Unicycive Therapeutics | 10-K: Annual report
Unicycive Therapeutics | D: Filing D
Unicycive Therapeutics | 8-K: Current report
Unicycive Therapeutics | 8-K: Current report
Unicycive Therapeutics | 8-K: Current report
Unicycive Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-RA Capital Management, L.P.(9.99%),Peter Kolchinsky(9.99%), etc.
Unicycive Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Nantahala Capital Management, LLC(9.9%),Wilmot B. Harkey(9.9%), etc.
Unicycive Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Armistice Capital, LLC(2.73%),Steven Boyd(2.73%)
Unicycive Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP(6.1%)
Unicycive Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Logos Global Management LP(9.9%),Logos Global Management GP LLC(9.9%), etc.
Unicycive Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Unicycive Therapeutics | 8-K: Unicycive Announces Third Quarter 2023 Financial Results and Provides Business Update
Unicycive Therapeutics: Q3 2023 Earnings Report
Unicycive Therapeutics | 8-K: Current report
Unicycive Therapeutics | 8-K: Current report
Unicycive Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Laumas Sandeep
Unicycive Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Kenkare-Mitra Sara
Unicycive Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Ryan John L
Unicycive Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Aggarwal Gaurav
Unicycive Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Kenkare-Mitra Sara
No Data